于明明

于明明

博士

副教授

硕士生导师

科 室：

药物分析研究室

办公电话：

0532-82032064

电子邮箱：

yumingming@ouc.edu.cn

联系地址：

山东省青岛市鱼山路5号中国海洋大学医药学院A203 266003

研究方向：

1. 临床前药物代谢与药物动力学研究

2. 定量药理学（PK/PD模型研究）

3. 新药研发过程中先导药物药代特性筛选和评价

个人简介

主要从事海洋来源活性成分和糖类药物的药物代谢动力学研究、临床群体PK/PD模型研究，主持并多次参与国家自然科学基金项目、山东省自然科学基金项目等，在国际SCI和国内核心期刊上发表30余篇学术研究论文。

教育背景

2013.09~2014.01

中国海洋大学

药物化学

博士

2013.01~2013.08

美国马里兰大学

定量药理学

联合培养博士研究生

2011.08~2012.12

美国佛罗里达大学

定量药理学

联合培养博士研究生

2010.09~2011.07

中国海洋大学

药物化学

博士

2007.09~2010.07

中国海洋大学

药物化学

硕士

2003.09~2007.06

中国海洋大学

药学

学士

工作经历

2017.12~今

中国海洋大学 医药学院

副教授

2015.10~2017.12

美国马里兰大学 药学院

博士后

2014.03~2015.09

上海药物研究所药物代谢中心

博士后

学术兼职

中国药理学会定量药理学专业委员会委员

承担课程

药物分析（本科生课程）

药物代谢动力学（研究生课程）

研究进展

利用现代分析方法和技术，开展药物分析新技术和新方法研究，为药物发现、疾病诊断等提供新方法；开展药物质量控制关键技术研究，药品质量标准研究，为安全、有效、合理用药提供科学依据；开展活性化合物体外吸收、代谢稳定性研究，早期筛选候选药物；开展体内微量药物及其代谢物的分离、分析方法研究，研究药物在生物体内的吸收、分布、生物转化和排泄等过程的特点和规律，为安全、有效、合理用药提供科学依据；利用建模与模拟技术对药代动力学、药效动力学、机体功能、疾病进程和试验过程等信息进行模型化研究，为优化临床给药方案和个性化治疗提供科学依据。

代表性成果

代表性论文

定量药理学研究相关文章：

1.         Zhu S, Zhang J, Lv Z, Zhu P, Oo C, Yu M*, Sy SKB*.2022. Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet 61:1427-1441.

2.         Zhu S, Song C, Zhang J, Diao S, Heinrichs TM, Martins FS, Lv Z, Zhu Y, Yu M*, Sy SKB*.2022. Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii. Front Microbiol 13:1013939.

3.         Zhang Y, Zhang R, Sy SKB, Li Z, Zhu S, Zhou M, Song C, Zhang J, Lv Z, Liu J, Qin L*, Yu M*,2022. Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of Riemerella anatipestifer in Ducks. Microb Drug Resist 28:832-840.

4.         Feng K, Jia N, Zhu P, Sy S, Liu Y, Dong D, Zhu S, Zhang J, Liu Y, Martins FS, Gong H, Lv Z, Yu M*, Sy SKB, Zhu Y.2021. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-beta-lactamases. J Antimicrob Chemother 76:2875-2883.

5.         Hassan HE, Kelly D, Honick M, Shukla S, Ibrahim A, Gorelick DA, Glassman M, McMahon RP, Wehring HJ, Kearns AM, Feldman S, Yu M, Bauer K, Wang JB*.2017. Pharmacokinetics and Safety Assessment of l-Tetrahydropalmatine in Cocaine Users: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Pharmacol 57:151-160.

6.         Yu M, Gao Z, Dai X, Gong H, Zhang L, Chen X, Zhong DF*, Sy SK*. 2017. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors. Clin Pharmacokinet 56:65-76.

7.         Gao ZW, Zhu YT, Yu MM, Zan B, Liu J, Zhang YF, Chen XY, Li XN, Zhong DF*.2015. Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model. Acta Pharmacol Sin 36:1528-36.

8.         de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR*.2014. Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis. Antimicrob Agents Chemother 58:6242-50.

药物分析、药代动力学及代谢组学研究相关文章

1.         Zhu S, Zhang J, Song C, Liu Y, Oo C, Heinrichs MT, Lv Z*, Zhu Y, Sy SKB*, Deng P, Yu M*.2022. Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii. Front Microbiol 13:1013934.

2.         Zhang Y, Lv J, Zhang J, Lv Z, Yu M*.2022. Lipidomic-based investigation into the therapeutic effects of polyene phosphatidylcholine and Babao Dan on rats with non-alcoholic fatty liver disease. Biomed Chromatogr 36:e5271.

3.         Zhang P, Zhang M, Dong K, Zhang Y, Yang S, Wang Y, Jiang T, Yu M*,  Lv Z*.2022. Evaluation of Chito-Oligosaccharide (COS) in Vitro and in Vivo: Permeability Characterization in Caco-2 Cells Monolayer and Pharmacokinetics Properties in Rats. Journal of Ocean University of China 21:782-788.

4.         Wang P, Zhang J, Zhan N, Yang S, Yu M*,  Liu H*.2022. The pharmacokinetic characteristics and excretion studies of fucosterol from Sargasssum fusiforme in rats. Biomed Chromatogr 36:e5309.

5.         Shin SH, Yu M, Hammell DC, Ghosh P, Raney SG, Hassan HE, Stinchcomb AL*.2022. Evaluation of in vitro/in vivo correlations for three fentanyl transdermal delivery systems using in vitro skin permeation testing and human pharmacokinetic studies under the influence of transient heat application. J Control Release 342:134-147.

6.         Liu Y, Zang X, Feng K, Liu S, Zhang J, Lv Z, Xin Y*, Yu M*.2022. Lipidomic Determination of Serum Lipids by Ultra-High Performance Liquid Chromatography – Mass Spectrometry (UPLC-MS) for the Characterization of Nonalcoholic Fatty Liver Disease (NAFLD). Analytical Letters 55:879-890.

7.         Liu G, Wang H, Lv Z, Tang X, Yu M*.2022. A comprehensive metabolomic and lipidomic analysis reveals the effect of temperature on flounder (Paralichthys olivaceus). J Therm Biol 104:103203.

8.         Liu G, Duan Y, Yang S, Yu M*, Lv Z*.2022. Simultaneous quantification of marine neutral neoagaro-oligosaccharides and agar-oligosaccharides by the UHPLC-MS/MS method: application to the intestinal transport study by using the Caco-2 cell monolayer. Anal Methods 14:2227-2234.

9.         Duan Y, Zuo Z, Chen Y, Song Q, Yu M*, Yang Y*.2022. A validated liquid chromatography-tandem mass spectrometry method for the determination of l-hyoscyamine in human plasma: Application in a clinical study. Biomed Chromatogr 36:e5485.

10.        Zhu S, Zhang J, Lv Z, Yu M*.2021. LC-MS/MS Determination of Apigenin in Rat Plasma and Application to Pharmacokinetic Study. Curr Pharm Biotechnol 22:274-280.

11.        Zhang P, Liu S, Yang S, Wang Y, Jiang T, Yu M*, Lv Z*.2021. Simultaneous determination of chito-oligosaccharides in rat plasma by the LC-MS/MS method: application to a pharmacokinetic study. Anal Methods 13:3242-3248.

12.        Zhang Y, Yin R, Wu G, Yu M, Liu J, Wang X, Liu X, Guan H, Yu R, Jiang T.2020. Self-assembling nanoparticles of dually hydrophobic prodrugs constructed from camptothecin analogue for cancer therapy. Eur J Med Chem 200:112365.

13.        Yang Y, Zhang P, Liu G, Yang S, Wang Y, Jiang T, Lv Z, Yu M*.2020. Simultaneous Quantification of κ-Carrageenan Oligosaccharides of DP 3, 5 and 7 by LC-MS/MS: Application to an in vitro Absorption Study. Journal of Ocean University of China 19:1177-1182.

14.        Lv J, Wang C, Zhang X, Lv Z*, Yu M*.2020. 1H NMR Quantification of DHA and EPA in Fish Oil. Journal of Ocean University of China 19:1193-1197.

15.        Yu M, Abdallah IA, Shin SH, Hammell DC, Stinchcomb AL*, Hassan HE*.2017. LC-MS determination of fentanyl in human serum and application to a fentanyl transdermal delivery pharmacokinetic study. Bioanalysis 9:1551-1560.

16.        Mingming Y, Yuanhong W, Fugang M, Weijie Y, Tingfu J, Zhihua LV*.2017. Pharmacokinetics, Tissue Distribution and Excretion Study of Fluoresceinlabeled PS916 in Rats. Curr Pharm Biotechnol 18:391-399.

17.        Yu M, Salvador LA, Sy SK, Tang Y, Singh RS, Chen QY, Liu Y, Hong J, Derendorf H, Luesch H*.2014. Largazole pharmacokinetics in rats by LC-MS/MS. Mar Drugs 12:1623-40.

18.        Yu M, Hassan HE, Ibrahim A, Bauer KS, Kelly DL, Wang JB*.2014. Simultaneous determination of L-tetrahydropalmatine and cocaine in human plasma by simple UPLC-FLD method: application in clinical studies. J Chromatogr B Analyt Technol Biomed Life Sci 965:39-44.

19.        Yu MM, Jiang TF, Wang YH, Wang DY, Lv ZH*.2013. Identification and analysis of an impurity inducing clinical adverse effect in anti-adhesion carboxymethyl chitosan products. J Pharm Biomed Anal 85:21-7.

项目课题

1.主持中国海洋大学“英才”三层次，非酒精性脂肪性肝病的脂质组学研究，2018/10-2021/09，在研，主持

2.山东省自然科学基金博士基金项目，ZR2017BC092，聚合度对壳寡糖的吸收转运过程和口服生物利用度的影响规律研究，2019/07-2022/6，在研，主持